MedTrace Logo

A Multicenter Clinical Trial of Sputum DNA Testing for Lung Cancer in China

NCT05337163 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1564

Last updated 2025-03-21

No results posted yet for this study

Summary

The primary objective of this study is to assess the safety and effectiveness of Human Multigene Methylation Detection Kit (Fluorescent PCR Method) for help diagnose lung cancer by comparing with clinical standard method (includes chest CT examination or pathological examination).

Conditions

Interventions

DIAGNOSTIC_TEST

Diagnostic Test: Sputum DNA methylation analysis

Diagnostic Test: sputum specimen will be collected by the subject for the detection of Human Multigene Methylation Detection Kit (Fluorescent PCR Method)

PROCEDURE

chest CT or pathological examination

Subjects will undergo chest CT or pathological examination.

Sponsors & Collaborators

  • Guangzhou Xiangkang Medical Research Co., Ltd.

    collaborator UNKNOWN

  • Creative Biosciences (Guangzhou) Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Lei Zheng, PhD · Nanfang Hospital of Southern Medccal University

  • Laiyu Liu, PhD · Nanfang Hospital of Southern Medccal University

Eligibility

Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-02-25
Primary Completion
2025-02-18
Completion
2025-03-05

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05337163 on ClinicalTrials.gov